Cargando…
Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma
Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Japanese Society of Internal Medicine
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184094/ https://www.ncbi.nlm.nih.gov/pubmed/31813918 http://dx.doi.org/10.2169/internalmedicine.3928-19 |